Clinical Trial Update: TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line Tafasitamab, Polatuzumab Vedotin, and Glofitamab for diffuse large B-cell lymphoma and high-grade B-cell lymphoma; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma

Drugs mentioned

• Glofitamab (glofitamab)
• polatuzumab vedotin (polatuzumab vedotin)
• tafasitamab (tafasitamab)

Snippet

Sponsor: Brown University | Conditions: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING